interleukin-10-eBrg

Interleukin-10-eBrg (IL-10-eBregs) is an engineered regulatory B cell therapy being developed for the treatment of autoimmune diseases, specifically multiple sclerosis. These cells are primary B cells modified using CRISPR/Cas9-mediated homology-directed repair (HDR) to constitutively express interleukin-10 (IL-10) and an antigen-specific B cell receptor (BCR), such as one targeting myelin oligodendrocyte glycoprotein (MOG), from the endogenous IgH locus. Additionally, the cells are engineered with a Blimp1 knockout to prevent differentiation into antibody-secreting plasma cells, allowing them to function as stable "decoy" B cells that outcompete endogenous B cells for T cell help. While IL-10-eBregs were found to increase activated CD4 T cell numbers in some in vitro assays, they are being investigated for their ability to modulate neuroinflammation in the central nervous system.

Other names

IL-10 engineered regulatory B cellsIL10 engineered regulatory B cellsIL 10 engineered regulatory B cellsMOG-specific IL-10-eBregs